Adoptive Cell Therapy Long-term Follow-up (LTFU) Study

NCT03391778 · tracked via the Priya Life Science UK tracker

Sponsor

USWM CT, LLC

Phase

Phase 1

Started

2018-04-09

Last updated

2026-08-11

Condition(s) studied

Neoplasms

Investigational drug(s) / intervention(s)

ADP adoptive cell therapy

ADP adoptive cell therapy: No study drug is administered in this study. Participants who received ADP adoptive cell therapy in a previous trial will be evaluated in this trial for long-term safety and efficacy.

Study summary

This trial will evaluate long term safety of participants who have received AdaptImmune (ADP) adoptive cell therapy for up to 15 years following last adoptive cell therapy infusion.

Eligibility

Sex

ALL

Min age

—

Max age

—

Healthy volunteers

Inclusion Criteria: * Participants who have received at least one dose of ADP adoptive cell therapy agent. * Participants who have completed ADP sponsored or supported interventional study or have withdrawn from it. * Participants who have completed treatment as part of managed access to a GSK adoptive cell therapy. * Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. * The investigator is responsible for review of medical history. * Capable of giving signed informed consent. Exclusion Criteria: \- None

Primary outcome measure(s)

Number of participants with delayed adverse events (AEs) and serious adverse events (SAEs) — 15 years post last treatment
AEs will be collected.

Trial sites (24)

Facility	City	Region
Emory University School of Medicine	Atlanta	Georgia
ADP Investigational Site	Baltimore	Maryland
National Cancer Institute - Center for Cancer Research	Bethesda	Maryland
University of Michigan	Ann Arbor	Michigan
Washington University School of Medicine in St. Louis	St Louis	Missouri
Memorial Sloan Kettering Cancer Center - New York	New York	New York
Duke University Medical Center	Durham	North Carolina
Oregon Health and Science University	Portland	Oregon
University of Pennsylvania	Philadelphia	Pennsylvania
University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center	Pittsburgh	Pennsylvania
University of Texas Southwestern Medical Center	Dallas	Texas
University of Texas MD Anderson Cancer Center	Houston	Texas
Froedtert Hospital	Milwaukee	Wisconsin
Peter MacCallum Cancer Centre	Melbourne	Victoria
Princess Margaret Cancer Centre	Toronto	Ontario
Hôpital Maisonneuve-Rosemont	Montreal	Quebec
Klinikum rechts der Isar der Technischen Universität München	Munich	Bavaria
Uniklinik Köln	Cologne	North Rhine-Westphalia
Fondazione IRCCS - Istituto Nazionale dei Tumori	Milan	Lombardy
Antoni Van Leeuwenhoek Ziekenhuis	Amsterdam	Netherlands
Hospital Universitario Virgen del Rocío	Seville	Spain
University College London Hospitals NHS Foundation Trust	London	United Kingdom
USWM CT Investigational Site	Manchester	United Kingdom
The Royal Marsden NHS Foundation Trust	Sutton	United Kingdom

More USWM CT, LLC trials in the UK

Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors Active, not recruiting

ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3) Active, not recruiting

Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma Active, not recruiting

Other trials for the same condition

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers Active, not recruiting

A Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injection in Participants With Advanced Solid Tumors (BEHOLD-1) Recruiting

A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD) Recruiting

Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors Active, not recruiting

A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03391778 on ClinicalTrials.gov ↗ ← All trials in the UK